Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24206632,Bioavailability,"Bioavailability for each route was almost complete, accounting for 94% and 90% after IM and SC administrations, respectively.","Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24206632/),%,94,17711,DB06204,Tapentadol
,24206632,Bioavailability,"Bioavailability for each route was almost complete, accounting for 94% and 90% after IM and SC administrations, respectively.","Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24206632/),%,90,17712,DB06204,Tapentadol
,24206632,half-life of the terminal portion,The half-life of the terminal portion of the plasma concentration curve was not significantly different between the three routes of administrations (2-3h).,"Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24206632/),h,2-3,17713,DB06204,Tapentadol
,29799633,flow rate,The analytes and internal standard were treated by methanol and then separated on a Phenomenex Kinetex® XB-C18 (2.1 × 50 mm × 2.6 μm) column at a flow rate of 0.3 mL/min.,Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),[ml] / [min],0.3,37247,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,222.2,37248,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,107.0,37249,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,293.2,37250,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,71.9,37251,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,307.1,37252,DB06204,Tapentadol
,29799633,m/z,"The mass transition ion-pairs were m/z 222.2 → 107.0, m/z 293.2 → 71.9 and m/z 307.1 → 220.0 for tapentadol, WWJ01 and IS, respectively.",Simultaneous determination of tapentadol and its carbamate prodrug in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29799633/),,220.0,37253,DB06204,Tapentadol
,32475909,clearance (CL/F),"The median (range) estimated clearance (CL/F) and distribution volume (Vd/F) of TP were 86.7 (31.3-213.7) L/h and 1288 (189-6736) L, respectively.","Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32475909/),[l] / [h],86.7,39544,DB06204,Tapentadol
,32475909,distribution volume (Vd/F),"The median (range) estimated clearance (CL/F) and distribution volume (Vd/F) of TP were 86.7 (31.3-213.7) L/h and 1288 (189-6736) L, respectively.","Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32475909/),l,1288,39545,DB06204,Tapentadol
,26798023,apparent oral clearance,"The population estimates of apparent oral clearance and apparent central volume of distribution were 257 L/h and 1870 L, respectively.",Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26798023/),[l] / [h],257,42196,DB06204,Tapentadol
,26798023,apparent central volume of distribution,"The population estimates of apparent oral clearance and apparent central volume of distribution were 257 L/h and 1870 L, respectively.",Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26798023/),l,1870,42197,DB06204,Tapentadol
,28242230,TT,Baseline TT was 45.4 ± 1.4 °C for all treatments.,Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,45.4,44226,DB06204,Tapentadol
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,48.8,44227,DB06204,Tapentadol
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,48.5,44228,DB06204,Tapentadol
,28242230,Maximum TT,"Maximum TT values were 48.8 ± 4.8 °C at 1 hour in LowTAP, 48.5 ± 3.0 °C at 2 hours in HighTAP and 50.2 ± 5.3 °C at 1 hour in BUP.",Thermal antinociception following oral administration of tapentadol in conscious cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28242230/),°c,50.2,44229,DB06204,Tapentadol
,24353023,terminal half-life,Mean terminal half-life values ranged from 4.4 to 5.9 hours.,Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353023/),h,4.4 to 5.9,49063,DB06204,Tapentadol
,24611613,Tmax,"After I.M. injection, TAP showed a very fast absorption (Tmax = 0.17 h) and a short half-life (1.29 h).","Use of the novel atypical opioid tapentadol in goats (Capra hircus): pharmacokinetics after intravenous, and intramuscular administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611613/),h,0.17,75747,DB06204,Tapentadol
,24611613,half-life,"After I.M. injection, TAP showed a very fast absorption (Tmax = 0.17 h) and a short half-life (1.29 h).","Use of the novel atypical opioid tapentadol in goats (Capra hircus): pharmacokinetics after intravenous, and intramuscular administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611613/),h,1.29,75748,DB06204,Tapentadol
,24611613,bioavailability,"The I.M. bioavailability was quite high, despite being variable (87.8 ± 35.6%).","Use of the novel atypical opioid tapentadol in goats (Capra hircus): pharmacokinetics after intravenous, and intramuscular administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611613/),%,87.8,75749,DB06204,Tapentadol
,31686902,apparent clearance,"Mean population apparent clearance and apparent volume of distribution for a typical subject weighing 45 kg were 170 L/h and 685 L, respectively.",Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31686902/),[l] / [h],170,77698,DB06204,Tapentadol
,31686902,apparent volume of distribution,"Mean population apparent clearance and apparent volume of distribution for a typical subject weighing 45 kg were 170 L/h and 685 L, respectively.",Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31686902/),l,685,77699,DB06204,Tapentadol
,22621882,flow rate,"The mobile phase consisted of acetonitrile (A):acetic acid (B) (33 mM), delivered in gradient mode (5-95% B [0-20 min], 95-5% B [20-25 min] and finally 5% B isocratically [25-32 min]) with a flow rate of 1 mL min⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),min⁻¹·ml,1,122791,DB06204,Tapentadol
,22621882,recovery,"TAP was extracted from the plasma using a mixture of Et₂O:CH₂Cl₂ (7:3, v/v), which gave a recovery of 98.0-107.8% and a limit of quantification of 1 ng mL⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),%,98.0-107.8,122792,DB06204,Tapentadol
,22621882,limit of quantification,"TAP was extracted from the plasma using a mixture of Et₂O:CH₂Cl₂ (7:3, v/v), which gave a recovery of 98.0-107.8% and a limit of quantification of 1 ng mL⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),ml⁻¹·ng,1,122793,DB06204,Tapentadol
,22771148,half-life,"After IV administration, concentrations of TAP were detectable in plasma for up to 6h with a half-life in the range 38-68 min.",Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771148/),min,38-68,124535,DB06204,Tapentadol
,22771148,bioavailability,"After oral administration, drug absorption was rapid (T(max), time required to reach the maximum concentration of 47.5 min), but its bioavailability was low (4.4%).",Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771148/),%,4.4,124536,DB06204,Tapentadol
,32064982,t1/2,"C-MB-NV showed improved pharmacokinetics parameters i.e. increased t1/2 (9.7 h), AUC (159.725 μg/mL*h), and MRT (14.99 h) of TAP than nontargeted formulation and plain drug soln.",Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064982/),h,9.7,126690,DB06204,Tapentadol
,32064982,AUC,"C-MB-NV showed improved pharmacokinetics parameters i.e. increased t1/2 (9.7 h), AUC (159.725 μg/mL*h), and MRT (14.99 h) of TAP than nontargeted formulation and plain drug soln.",Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064982/),[μg] / [h·ml],159.725,126691,DB06204,Tapentadol
,32064982,MRT,"C-MB-NV showed improved pharmacokinetics parameters i.e. increased t1/2 (9.7 h), AUC (159.725 μg/mL*h), and MRT (14.99 h) of TAP than nontargeted formulation and plain drug soln.",Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064982/),h,14.99,126692,DB06204,Tapentadol
,18062408,maximum serum concentration [Cmax],"Absorption was rapid (with a mean maximum serum concentration [Cmax], 2.45 microg-eq/ml; a time to Cmax, 1.25-1.5 h), and the drug was present primarily in the form of conjugated metabolites (conjugated:unconjugated metabolites = 24:1).","Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),[μg-eq] / [ml],2.45,158284,DB06204,Tapentadol
,18062408,time to Cmax,"Absorption was rapid (with a mean maximum serum concentration [Cmax], 2.45 microg-eq/ml; a time to Cmax, 1.25-1.5 h), and the drug was present primarily in the form of conjugated metabolites (conjugated:unconjugated metabolites = 24:1).","Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),h,1.25-1.5,158285,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),%,95,158286,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),%,99.,158287,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),%,99,158288,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),,69,158289,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),,27,158290,DB06204,Tapentadol
,18062408,Excretion,Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and almost exclusively renal (99%: 69% conjugates; 27% other metabolites; 3% in unchanged form).,"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062408/),,3,158291,DB06204,Tapentadol
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB06204,Tapentadol
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB06204,Tapentadol
,29115161,minimal effective concentration,"Following IV administration, TAP plasma concentrations were only higher than the minimal effective concentration (148 ng/ml) reported for humans for 1 h.",Pharmacokinetics of tapentadol in laying hens and its residues in eggs after multiple oral dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115161/),[ng] / [ml],148,204868,DB06204,Tapentadol
,26677859,drug release,All the batches showed a drug release ranging from 29.87 to 56.92% after 12 h; and from 59.64 to 99.96% after 24 h.,Development and Evaluation of a Once-Daily Controlled Porosity Osmotic Pump of Tapentadol Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26677859/),%,29.87 to 56.92,209976,DB06204,Tapentadol
,26677859,drug release,All the batches showed a drug release ranging from 29.87 to 56.92% after 12 h; and from 59.64 to 99.96% after 24 h.,Development and Evaluation of a Once-Daily Controlled Porosity Osmotic Pump of Tapentadol Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26677859/),%,59.64 to 99.96,209977,DB06204,Tapentadol
,33892588,peak concentration (Cmax),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),[ng] / [ml],143,216544,DB06204,Tapentadol
,33892588,half-life (T 1/2),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),min,24.8,216545,DB06204,Tapentadol
,23357834,Absolute bioavailability,"Absolute bioavailability was estimated to be 32% (95% confidence interval (CI), 29.4 - 34.8%; n = 24) for tapentadol IR 86 mg and 32% (95% CI, 28.0 - 35.9%; n = 18) for tapentadol PR 86 mg.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),%,32,236654,DB06204,Tapentadol
,23357834,Absolute bioavailability,"Absolute bioavailability was estimated to be 32% (95% confidence interval (CI), 29.4 - 34.8%; n = 24) for tapentadol IR 86 mg and 32% (95% CI, 28.0 - 35.9%; n = 18) for tapentadol PR 86 mg.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),%,32,236655,DB06204,Tapentadol
,23357834,relative bioavailability,"Based on AUC, the relative bioavailability of tapentadol PR vs. tapentadol IR was 96% (90% CI, 87.8 - 104.4%; n = 16).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),%,96,236656,DB06204,Tapentadol
,23357834,elimination half-life,"Following IV administration, tapentadol had an elimination half-life of about 4 hours; in Studies 1 and 2, respectively, mean tapentadol volumes of distribution were 540 and 471 l, and mean clearance was 1,531 and 1,603 ml/min.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,4,236657,DB06204,Tapentadol
,23357834,volumes of distribution,"Following IV administration, tapentadol had an elimination half-life of about 4 hours; in Studies 1 and 2, respectively, mean tapentadol volumes of distribution were 540 and 471 l, and mean clearance was 1,531 and 1,603 ml/min.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),l,540,236658,DB06204,Tapentadol
,23357834,volumes of distribution,"Following IV administration, tapentadol had an elimination half-life of about 4 hours; in Studies 1 and 2, respectively, mean tapentadol volumes of distribution were 540 and 471 l, and mean clearance was 1,531 and 1,603 ml/min.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),l,471,236659,DB06204,Tapentadol
,23357834,clearance,"Following IV administration, tapentadol had an elimination half-life of about 4 hours; in Studies 1 and 2, respectively, mean tapentadol volumes of distribution were 540 and 471 l, and mean clearance was 1,531 and 1,603 ml/min.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),[ml] / [min],"1,531",236660,DB06204,Tapentadol
,23357834,clearance,"Following IV administration, tapentadol had an elimination half-life of about 4 hours; in Studies 1 and 2, respectively, mean tapentadol volumes of distribution were 540 and 471 l, and mean clearance was 1,531 and 1,603 ml/min.",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),[ml] / [min],"1,603",236661,DB06204,Tapentadol
,23357834,Cmax,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),[ng] / [ml],22.5,236662,DB06204,Tapentadol
,23357834,Cmax,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),[ng] / [ml],64.2,236663,DB06204,Tapentadol
,23357834,time to Cmax,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,5.0,236664,DB06204,Tapentadol
,23357834,time to Cmax,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,1.5,236665,DB06204,Tapentadol
,23357834,half-value duration (HVD,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,12.5,236666,DB06204,Tapentadol
,23357834,half-value duration (HVD,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,3.6,236667,DB06204,Tapentadol
,23357834,mean residence time (MRT,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,10.6,236668,DB06204,Tapentadol
,23357834,mean residence time (MRT,"Compared to tapentadol IR 86 mg, the prolonged-release characteristics of tapentadol PR 86 mg were evident with a lower Cmax (22.5 ng/ml vs. 64.2 ng/ml), a longer time to Cmax (5.0 h vs. 1.5 h), a higher half-value duration (HVD: 12.5 h vs. 3.6 h), and a longer mean residence time (MRT: 10.6 h vs. 6.0 h).",Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),h,6.0,236669,DB06204,Tapentadol
,23357834,Absolute bioavailability,Absolute bioavailability for both tapentadol IR and tapentadol PR was ~ 32% under fasted conditions.,Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357834/),%,32,236670,DB06204,Tapentadol
,31303784,Maximum serum concentrations,"Maximum serum concentrations of tapentadol (111 ng/mL) and tapentadol-O-glucuronide (2,400 ng/mL) observed in this trial were within the range of individual maximum concentrations observed in healthy adults administered a comparable dose (range for tapentadol 23.2-129 ng/mL, for tapentadol-O-glucuronide 1,040-4,070 ng/mL).",First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303784/),[ng] / [ml],111,239270,DB06204,Tapentadol
,31303784,Maximum serum concentrations,"Maximum serum concentrations of tapentadol (111 ng/mL) and tapentadol-O-glucuronide (2,400 ng/mL) observed in this trial were within the range of individual maximum concentrations observed in healthy adults administered a comparable dose (range for tapentadol 23.2-129 ng/mL, for tapentadol-O-glucuronide 1,040-4,070 ng/mL).",First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303784/),[ng] / [ml],"2,400",239271,DB06204,Tapentadol
,31303784,Maximum serum concentrations,"Maximum serum concentrations of tapentadol (111 ng/mL) and tapentadol-O-glucuronide (2,400 ng/mL) observed in this trial were within the range of individual maximum concentrations observed in healthy adults administered a comparable dose (range for tapentadol 23.2-129 ng/mL, for tapentadol-O-glucuronide 1,040-4,070 ng/mL).",First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303784/),[ng] / [ml],"1,040-4,070",239272,DB06204,Tapentadol
,29583048,maximum plasma concentrations,"Mean maximum plasma concentrations after 10, 20, and 30 mg/kg were 10.2, 19.7, and 31 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),[ng] / [ml],10.2,258244,DB06204,Tapentadol
,29583048,maximum plasma concentrations,"Mean maximum plasma concentrations after 10, 20, and 30 mg/kg were 10.2, 19.7, and 31 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),[ng] / [ml],19.7,258245,DB06204,Tapentadol
,29583048,maximum plasma concentrations,"Mean maximum plasma concentrations after 10, 20, and 30 mg/kg were 10.2, 19.7, and 31 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),[ng] / [ml],31,258246,DB06204,Tapentadol
,29583048,plasma half-life of the terminal phase,"Geometric mean plasma half-life of the terminal phase after tapentadol administration at 10, 20, and 30 mg/kg was 3.5 hours (range, 2.7 to 4.5 hours), 3.7 hours (range, 3.1 to 4.0 hours), and 3.7 hours (range, 2.8 to 6.5 hours), respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),h,3.5,258247,DB06204,Tapentadol
,29583048,plasma half-life of the terminal phase,"Geometric mean plasma half-life of the terminal phase after tapentadol administration at 10, 20, and 30 mg/kg was 3.5 hours (range, 2.7 to 4.5 hours), 3.7 hours (range, 3.1 to 4.0 hours), and 3.7 hours (range, 2.8 to 6.5 hours), respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),h,3.7,258248,DB06204,Tapentadol
,29583048,plasma half-life of the terminal phase,"Geometric mean plasma half-life of the terminal phase after tapentadol administration at 10, 20, and 30 mg/kg was 3.5 hours (range, 2.7 to 4.5 hours), 3.7 hours (range, 3.1 to 4.0 hours), and 3.7 hours (range, 2.8 to 6.5 hours), respectively.",Pharmacokinetics and pharmacodynamics after oral administration of tapentadol hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29583048/),h,3.7,258249,DB06204,Tapentadol
,23878616,half-life,The half-life of the drug is about 4 hours and oral dose is 50 to 250 mg twice a day.,Application of design of experiment for floating drug delivery of tapentadol hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23878616/),h,4,261406,DB06204,Tapentadol
